drugset / Trial / NCT05679102

Atorvastatin as an Antihypertensive Agent

NCT05679102

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is aimed to see the antihypertensive effect of statin (Atorvastatin) as certain animal models have shown that statins have the voltage-gated calcium channel blocking effect. It will be a randomized controlled trial that will be done in Ayub Hospital Complex Abbottabad. After ethical approval, 120 patients with newly diagnosed hypertension belonging to either gender and aged 35 and above will be enrolled in the trial. They will randomly be grouped into two groups with each group comprising 60 patients. One group will be administered Amlodipine 5 mg PO once a day, while the other one will be given 5mg Amlodipine plus 10 mg Atorvastatin. The patients will be examined on a follow-up visit 14 days later and blood pressure will be recorded as per protocols.

Timeline

Start
2022-12-20
Primary completion
2023-01-04
Completion
2023-01-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 10 mg Oral
Comparator Amlodipine Other / unclassified 5 mg Oral

Indications

No indication recorded.